Literature DB >> 11720839

Genetic epidemiology of BRCA1 mutations in Norway.

P Møller1, K Heimdal, J Apold, A Fredriksen, A Borg, E Hovig, A Hagen, B Hagen, J C Pedersen, L Maehle.   

Abstract

Familial breast-ovarian cancer has been demonstrated to be frequent but unevenly distributed in Norway. This was assumed to be caused by the reduced population size created by the medieval Bubonic plagues 25 generations ago, and by the following rapid expansion. We have previously reported that four mutations account for 68% of the BRCA1 mutation carriers. Subsequent analysis has resulted in a total of 100 separate families carrying one of these founder mutations. The four mutations occurred on one specific BRCA1 haplotype each. The 1675delA, 816delGT and 3347delAG families originated from the South-West coast of Norway with a few families in the north, while the traceable ancestors of the 1135insA families clustered along the historical inland road from the South-East to mid-Norway. The carriers of each of the four mutations today are descendants of one or a few individuals surviving the plagues. We may identify the majority of BRCA1 mutation carriers in Norway by screening for local founder mutations.

Entities:  

Mesh:

Year:  2001        PMID: 11720839     DOI: 10.1016/s0959-8049(01)00299-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  15 in total

1.  Uptake of BRCA1 genetic testing in adult sisters and daughters of known mutation carriers in Norway.

Authors:  Trine Levin Bodd; Jon Reichelt; Ketil Heimdal; Pal Moller
Journal:  J Genet Couns       Date:  2003-10       Impact factor: 2.537

Review 2.  Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.

Authors:  Elisabete Weiderpass; Jerzy E Tyczynski
Journal:  Mol Diagn Ther       Date:  2015-12       Impact factor: 4.074

Review 3.  Mutations in context: implications of BRCA testing in diverse populations.

Authors:  Gabriela E S Felix; Yonglan Zheng; Olufunmilayo I Olopade
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

4.  Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations.

Authors:  Amy Østertun Geirdal; Jon G Reichelt; Alv A Dahl; Ketil Heimdal; Lovise Maehle; Astrid Stormorken; Pål Møller
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  BRCA1 testing with definitive results: a prospective study of psychological distress in a large clinic-based sample.

Authors:  Jon G Reichelt; Ketil Heimdal; Pål Møller; Alv A Dahl
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

6.  The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations.

Authors:  Teresa M Rudkin; Nancy Hamel; Maria Galvez; Frans Hogervorst; Johan J P Gille; Pål Møller; Jaran Apold; William D Foulkes
Journal:  BMC Med Genet       Date:  2006-03-01       Impact factor: 2.103

7.  No sib pair concordance for breast or ovarian cancer in BRCA1 mutation carriers.

Authors:  Pål Møller; Lovise Maehle; Neal Clark; Jaran Apold
Journal:  Hered Cancer Clin Pract       Date:  2007-06-15       Impact factor: 2.857

8.  Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population.

Authors:  Abdelilah Laraqui; Nancy Uhrhammer; Idriss Lahlou-Amine; Hicham El Rhaffouli; Jamila El Baghdadi; Mohamed Dehayni; Rahali Driss Moussaoui; Mohamed Ichou; Yassir Sbitti; Abderrahman Al Bouzidi; Said Amzazi; Yves-Jean Bignon
Journal:  Int J Med Sci       Date:  2012-12-10       Impact factor: 3.738

9.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

10.  BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.

Authors:  T Bjørge; A K Lie; E Hovig; R E Gislefoss; S Hansen; E Jellum; H Langseth; K Nustad; C G Tropé; A Dørum
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.